Please login to the form below
Data by
22
Revenue 2014Daiichi Sankyo
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.
Astellas extends phase III programme for Rydapt rival gilteritinib
Two other FLT3 inhibitors - Daiichi Sankyo's quizartinib and Arog Pharma's crenolanib - are also in late-stage testing.
Daiichi drug hits mark in shingles pain, but misses in other indications
Daiichi Sankyo's mirogabalin has shown efficacy in a phase III trial involving patients with post-herpetic neuralgia (PHN), the persistent and often excruciating pain that can follow shingles. ... What is clear however is that the results of the ALDAY
Novartis' Rydapt approval ends long AML therapy drought
Daiichi Sankyo's quizartinib - acquired along with Ambit Biosciences' for $410m in 2014 - and Arog Pharma's crenolanib are both in phase III testing in FLT3-positive AML.
Japanese pharma pulls no punches with post-Brexit UK
The level of investment on the pharmaceutical side is considerable. The Japanese Pharmaceutical Group (JPG), an association of nine drugmakers - Astellas, Chugai, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi Tanabe, Otsuka, Shionogi and
Deal Watch March 2017
Resarci out-licensed ACAT-1 to Xynomic, as detailed above, and Daiichi Sankyo paid $4m upfront, committed $8m in research funding and further research, development and commercialisation milestone payments for the ... 20. Heptares/ Sosei Group. Daiichi
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| Japan revenue 2014 |
|---|
| 1: Takeda |
| 2: Otsuka |
| 3: Meiji |
| 4: Astellas |
| 5: Daiichi Sankyo |
| 6: Teijin |
| 7: Eisai |
| 8: Chugai |
| 9: Mitsubishi Tanabe |
| 10: Kyowa Hakko Kirin |
| 11: Taisho |
| 12: Shionogi |
| 13: Hisamitsu |
| 14: Santen |
| 15: Ono |
| 16: Kyorin |
| 17: Nichi-Iko |
| 18: Mochida |
| 19: Sawai |
| 20: Kaken |
| 21: Kissei |
| 22: Zeria |
| 23: Towa |
| 24: Torii |
| 25: Daito |
| Immunology revenue 2014 |
|---|
| 1: AbbVie |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Amgen |
| 5: Merck & Co. |
| 6: Astellas |
| 7: Roche |
| 8: Novartis |
| 9: Bristol-Myers Squibb |
| 10: Mitsubishi Tanabe |
| 11: UCB |
| 12: Hisamitsu |
| 13: Daiichi Sankyo |
| 14: Takeda |
| Cardiovascular revenue 2014 |
|---|
| 1: AstraZeneca |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Daiichi Sankyo |
| 5: Pfizer |
| 6: Novartis |
| 7: Bayer |
| 8: Takeda |
| 9: Boehringer Ingelheim |
| 10: Astellas |
| 11: Actelion |
| 12: Johnson & Johnson |
| 13: Shionogi |
| 14: United Therapeutics |
| 15: Bristol-Myers Squibb |
| 16: Gilead Sciences |
| 17: Otsuka |
| 18: Roche |
| 19: Lilly |
| 20: The Medicines Company |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
- Freelance Medical Copywriter, Healthcare Advertising Agency
-
according to skills and experience
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Editorial Director - BioScience
-
Competitive Salary
- Senior Account Manager/ Account Director – Pharma and Life Scien...
-
Competitive Salary
- Principal Medical Writer, Medical Education Agency
-
£46, 000 – £56, 000 benefits
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager, Medical Communications
-
£30, 000-£40, 000
-
Principal Medical Writer
-
Great salary and benefits
- Director of Scientific and Editorial Services
-
Great salary and benefits - Circa 100K
- Account Manager – Healthcare Advertising
-
Salary TBC
-
Brand Manager
-
Competitive salary and package
- Head of Communications - Based Cambridge
-
Excellent Basic and Flex Benefits
- JAM – Med Comms – Independent Agency
-
Salary TBC
- Account Executive - Pharma and Life Sciences Brighton or Maccles...
-
Competitive Salary
Subscribe to our email news alerts
- Novartis trial marks ResearchKit first in MS
- Ocrevus off to a flying start as Roche raises 2017 forecasts
- Samsung deal with Takeda looks beyond biosimilars
- NICE set to reject Pfizer's leukaemia drug Besponsa
- Novo's semaglutide beats Lilly's Trulicity in diabetes contest
- Biocon backs away from biosimilar filings in Europe
- Hugh Cole joins Jounce Therapeutics as chief business officer
- PharmaLex appoints Dr Adam King to its regulatory team
- The Pharma Wars Series
- Ironwood claims FDA OK for former AZ gout drug
- Astellas extends phase III programme for Rydapt rival gilteritinib
- What pharma marketers can learn from growth hacking?
PMHub
Quintiles
With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...
Latest intelligence
- The Pharma Wars Series
- The future galaxy is complex. Where markets are more competitive and customers more segmented, you’ve got to be smarter. But not only smarter, the Jedi today needs to be everywhere...
- What pharma marketers can learn from growth hacking?
- Growth hackers instinctively blend technical skills with creative thinking...
- The sound of silence puts the squeeze on generics and biosimilars
- Medicines for Europe vows to get governments talking to realise potential...
Quick links
Infographics
